Olivia Kyusuk Bloom - 15 Aug 2023 Form 4 Insider Report for GERON CORP (GERN)

Reporting relationship: EVP, Chief Financial Officer
Issuer ticker: GERN
Reported as of: 15 Aug 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 21 Sep 2023, 20:31:15 UTC
Prior SEC filing: 19 May 2023
Next SEC filing: 21 May 2024
Source filing: View source filing
Reporting owner signature: /s/ Olivia K. Bloom

Key filing fact

Olivia Kyusuk Bloom filed Form 4 for GERON CORP (GERN) on 21 Sep 2023.

Key facts

This page summarizes Olivia Kyusuk Bloom's Form 4 filing for GERON CORP (GERN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 21 Sep 2023, 20:31.

Change

Previous filing in this sequence was filed on 19 May 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GERN transaction Derivative

Employee Stock Option (right to buy)

Award

Transaction value: $0
Shares: +250,000
Change %
Price: $0.000000
Shares after: 250,000
Date: 15 Aug 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 250,000
Exercise price: $1.72
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Performance-based stock option granted on November 7, 2018 and vested in full on August 15, 2023 upon acceptance of the NDA by the US FDA for imetelstat in lower risk MDS.